Johnson & Johnson (JNJ) Free Cash Flow (2009 - 2026)
Johnson & Johnson (JNJ) posted Free Cash Flow of $7.3 billion for Q2 2026, up 397.95% sequentially from $1.5 billion in Q1 2026, and up 157.32% YoY from $2.8 billion in Q2 2025.
Johnson & Johnson (JNJ) Free Cash Flow (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Free Cash Flow for 18 years, with the latest figure at $7.3 billion in Q2 2026.
- Quarterly Free Cash Flow rose 157.32% year-over-year to $7.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $22.2 billion (up 19.92% YoY) and the FY2025 annual result came in at $19.7 billion, down 0.73% from the prior year.
- Free Cash Flow climbed to $7.3 billion in Q2 2026 per JNJ's latest filing, from $1.5 billion in the prior quarter.
- Over five years, Free Cash Flow peaked at $8.0 billion in Q3 2025 and troughed at $1.5 billion in Q1 2026.
- A 5-year average of $4.5 billion and a median of $4.0 billion in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2026: Free Cash Flow jumped 259.75% in 2023, then sank 56.64% in 2026.
- Over 5 years, Free Cash Flow stood at $3.4 billion in 2022, then soared by 86.06% to $6.3 billion in 2023, then retreated by 14.39% to $5.4 billion in 2024, then climbed by 1.88% to $5.5 billion in 2025, then jumped by 33.32% to $7.3 billion in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $7.3 billion, $1.5 billion, and $5.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.56 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 302.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 7.30 Bn |
| Jun 28, 2026 | 7.30 Bn |
| Mar 29, 2026 | 1.47 Bn |
| Mar 29, 2026 | 1.47 Bn |
| Dec 28, 2025 | 5.47 Bn |
| Dec 28, 2025 | 5.47 Bn |
| Sep 28, 2025 | 8.01 Bn |
| Sep 28, 2025 | 8.01 Bn |
| Jun 29, 2025 | 2.84 Bn |
| Jun 29, 2025 | 2.84 Bn |
| Mar 30, 2025 | 3.38 Bn |
| Mar 30, 2025 | 3.38 Bn |
| Dec 29, 2024 | 5.37 Bn |
| Dec 29, 2024 | 5.37 Bn |
| Sep 29, 2024 | 6.96 Bn |
| Sep 29, 2024 | 6.96 Bn |
| Jun 30, 2024 | 4.66 Bn |
| Jun 30, 2024 | 4.66 Bn |
| Mar 31, 2024 | 2.85 Bn |
| Mar 31, 2024 | 2.85 Bn |